Article
Combination Treatment Strategies to Overcome PARP Inhibitor Resistance
3 Oct 2023
Abstract excerpt
Poly(ADP-ribose) polymerase (PARP) enzymes have been shown to be essential for DNA repair pathways, including homologous recombination repair (HRR). Cancers with HRR defects (e.g., BRCA1 and BRCA2 mutations) are targets for PARP inhibitors (PARPis) based on the exploitation of "synthetic lethality". As a result, PARPis offer a promising treatment option for advanced ovarian and breast cancers with deficiencies in...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
